These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10551494

  • 1. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
    Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ.
    Lancet; 1999 Oct 30; 354(9189):1493-8. PubMed ID: 10551494
    [Abstract] [Full Text] [Related]

  • 2. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
    Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ.
    J Thorac Cardiovasc Surg; 2001 Apr 30; 121(4):714-22. PubMed ID: 11279413
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
    Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, PREVENT IV Investigators.
    JAMA; 2005 Nov 16; 294(19):2446-54. PubMed ID: 16287955
    [Abstract] [Full Text] [Related]

  • 4. E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
    Mann MJ.
    Antisense Nucleic Acid Drug Dev; 1998 Apr 16; 8(2):171-6. PubMed ID: 9593059
    [No Abstract] [Full Text] [Related]

  • 5. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
    Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, Tomita N, Amano J, Kaneda Y, Ogihara T, Takamoto S, Isobe M.
    Circ Res; 2000 Nov 24; 87(11):1063-8. PubMed ID: 11090553
    [Abstract] [Full Text] [Related]

  • 6. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.
    Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL.
    Vasc Endovascular Surg; 2005 Nov 24; 39(1):15-23. PubMed ID: 15696244
    [Abstract] [Full Text] [Related]

  • 7. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease.
    Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ.
    Circulation; 2002 Apr 09; 105(14):1686-92. PubMed ID: 11940548
    [Abstract] [Full Text] [Related]

  • 8. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
    Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.
    Proc Natl Acad Sci U S A; 1995 Jun 20; 92(13):5855-9. PubMed ID: 7597041
    [Abstract] [Full Text] [Related]

  • 9. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.
    Tomita N, Kim JY, Gibbons GH, Zhang L, Kaneda Y, Stahl RA, Ogborn M, Venderville B, Morishita R, Baran D, Dzau VJ.
    Int J Mol Med; 2004 May 20; 13(5):629-36. PubMed ID: 15067361
    [Abstract] [Full Text] [Related]

  • 10. Early growth response gene-1 decoy oligonucleotides inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of autogenous vein graft in rabbits.
    Wang X, Mei Y, Ji Q, Feng J, Cai J, Xie S.
    Interact Cardiovasc Thorac Surg; 2015 Jul 20; 21(1):50-4. PubMed ID: 25820759
    [Abstract] [Full Text] [Related]

  • 11. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
    Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D, Dzau VJ.
    Am J Physiol; 1998 Aug 20; 275(2):F278-84. PubMed ID: 9691019
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.
    Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwar YS, Makino H.
    J Clin Invest; 1998 Jun 01; 101(11):2589-97. PubMed ID: 9616230
    [Abstract] [Full Text] [Related]

  • 13. E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
    Cho WH, Lee SO, Kim HT, Ahn JD, Lee IK.
    Transplant Proc; 2005 Jun 01; 37(1):77-9. PubMed ID: 15808553
    [Abstract] [Full Text] [Related]

  • 14. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
    Yoshida M, Yamamoto N, Nitta T, Uehara T, Terao R, Hatano E, Iimuro Y, Yamaoka Y.
    J Surg Res; 2002 Feb 01; 102(2):95-101. PubMed ID: 11796004
    [Abstract] [Full Text] [Related]

  • 15. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model.
    Miyake T, Aoki M, Shiraya S, Tanemoto K, Ogihara T, Kaneda Y, Morishita R.
    J Mol Cell Cardiol; 2006 Sep 01; 41(3):431-40. PubMed ID: 16762361
    [Abstract] [Full Text] [Related]

  • 16. The role of ex-vivo gene therapy of vein grafts with Egr-1 decoy in the suppression of intimal hyperplasia.
    Peroulis M, Kakisis J, Kapelouzou A, Giagini A, Giaglis S, Mantziaras G, Kostomitsopoulos N, Karayannacos P, Macheras A.
    Eur J Vasc Endovasc Surg; 2010 Aug 01; 40(2):216-23. PubMed ID: 20537569
    [Abstract] [Full Text] [Related]

  • 17. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
    Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU, Park JY, Lee HW, Kim YH, Lee IK.
    Gene Ther; 2002 Dec 01; 9(24):1682-92. PubMed ID: 12457282
    [Abstract] [Full Text] [Related]

  • 18. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
    Nakamura T, Morishita R, Asai T, Tsuboniwa N, Aoki M, Sakonjo H, Yamasaki K, Hashiya N, Kaneda Y, Ogihara T.
    Gene Ther; 2002 Apr 01; 9(8):488-94. PubMed ID: 11948373
    [Abstract] [Full Text] [Related]

  • 19. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor.
    Akimoto M, Hangai M, Okazaki K, Kogishi J, Honda Y, Kaneda Y.
    Exp Eye Res; 1998 Oct 01; 67(4):395-401. PubMed ID: 9820786
    [Abstract] [Full Text] [Related]

  • 20. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW.
    Oncogene; 1994 Feb 01; 9(2):405-15. PubMed ID: 8290253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.